Eli Lilly (NEO:LLY)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Eli Lilly Charts. Click Here for more Eli Lilly Charts.](/p.php?pid=staticchart&s=NEO%5ELLY&p=8&t=15)
New Data Show Gemzar(R)-Based Combination Therapies May Provide
Significant Clinical Value in Early-Stage Non-Small Cell Lung Cancer
INDIANAPOLIS, May 17 /PRNewswire-FirstCall/ -- Data presented today(1,2,3)
from ongoing clinical trials show that therapies based on Eli Lilly and
Company's (LLY) Gemzar(R) (gemcitabine, HCl) administered prior to surgery have
a positive impact on survival, tumor shrinkage and quality of life among
patients with early-stage non-small cell lung cancer (NSCLC). Gemzar, which is
approved in various countries for the treatment of lung, breast, pancreatic,
bladder, ovarian and cervical cancers, is one of the most highly studied
anti-cancer agents in the world and these findings add to the body of evidence
of Gemzar's efficacy in another stage of lung cancer.
The study results, presented at the 41st annual meeting of the American Society
of Clinical Oncology (ASCO), are part of the ongoing GINEST Project, which is a
dual-clinical trial project evaluating the effectiveness of Gemzar in
combination with other leading chemotherapy agents in the treatment of Stage I
or II non-small cell lung cancer.
"Unfortunately, the risk of recurrence of lung cancer is a major problem even
in early stages of the disease," said Richard Gralla, M.D., president of the
New York Lung Cancer Alliance and a GINEST investigator. "Traditionally,
treatment of Stage I or II non-small cell lung cancer has only involved
surgery. The goal of administering these regimens prior to surgery is to treat
any microscopic spread of disease and shrink the tumor to enhance the
likelihood of surgical removal of the tumor. As we continue this project, we
hope to learn which chemotherapy regimens produce the best results, and do so
safely while maintaining or improving patients' quality of life."
Study Highlights
* Pre-operative therapy with Gemzar plus platinum or non-platinum agents was
highly tolerable, allowing 77 percent of patients to proceed to surgical
removal of the tumor; of these patients, 90 percent have had complete removal
of their lung cancer. Treatment with Gemzar-based therapy also demonstrated a
one-year survival rate of 74 percent in clinical study.(4)
* Pulmonary function testing (assessment of how well the lungs are working)
and dyspnea scores (assessment of breathing difficulties) obtained pre- and
post-chemotherapy to assess drug-induced injury to the lungs and effect on the
ability to undergo surgery confirmed the safety of these regimens. Of the 62
patients evaluated, only two were unable to undergo surgery because of reduced
lung function, and no patients experienced severe respiratory problems.(5)
* At six months after surgery, 78 percent of patients rated their quality of
life as improved or stable.(6)
* Seven patients reported worsening of quality of life due to undergoing more
than one operation and/or advancing to Stage III lung cancer. The decreased
quality of life did not seem to be a result of the chemotherapy regimen.(7)
* The most common side effects were blood-related:
-- Twenty-four patients (30 percent) experienced Grade 3/4 leukopenia
(an abnormal decrease in the number of white blood cells); and 8
patients (10 percent) experienced Grade 3/4 thrombocytopenia (a
decrease in the number of platelets in the blood, resulting in the
potential for increased bleeding and decreased ability for
clotting).(8)
According to the World Health Organization, approximately 1.2 million people
globally will be diagnosed with lung cancer this year.(9) It is the most
lethal of all cancers. About 80 percent of all lung cancer diagnoses are of
the non-small cell variety. As with any cancer, early detection and treatment
of lung cancer provides the best hope for managing the disease effectively.
"Gemzar has a strong heritage in the treatment of advanced non-small cell lung
cancer," said Coleman Obasaju, MD, U.S. oncology medical director at Lilly.
"Gemzar's ability to demonstrate efficacy with a wide array of chemotherapeutic
regimens makes it a cornerstone of lung cancer therapy."
GINEST Methods
Eighty-two patients with clinical Stage I (24 percent) and Stage II (76
percent) NSCLC were randomized and treated with chemotherapy prior to surgery.
In the first trial, 54 patients were treated with either Gemzar 1000 mg plus
carboplatin, or Gemzar 1000 mg plus paclitaxel 200 mg. In the second trial, 28
patients received the same regimen of Gemzar/carboplatin, or Gemzar 1000 mg
plus cisplatin 75 mg. Each combination was given for three cycles every 21
days. In the quality of life evaluation, the analysis compares patient-
determined quality of life ratings from baseline to 6 months after surgery
(total 9-month evaluation period). This ongoing portion of the study includes
33 patients (48 percent male, 52 percent female) at an average age of 63, 94
percent of whom underwent surgery. Patients completed the Lung Cancer Symptom
Scale (LCSS) (an instrument used to assess health-related quality of life in
patients with lung cancer) at baseline and every three months after surgery.
Gemzar
Gemzar is one of the most widely studied treatments in the history of
chemotherapy agents, and has been approved for use in more than 90 countries
worldwide. It is the worldwide standard for care of pancreatic cancer and in
many parts of the world for non-small cell lung, bladder and breast cancers.
Gemzar is approved in more than 60 countries as a single agent for the
treatment of locally advanced or metastatic pancreatic cancer. It is also
approved, in combination with Taxol(R) (paclitaxel), in more than 30 countries
for the treatment of metastatic breast cancer. In most European countries,
Gemzar is approved as a single agent or in combination with cisplatin for the
treatment of advanced non-small cell lung cancer. Gemzar, in combination with
carboplatin, is approved in several European markets for the treatment of
recurrent epithelial ovarian cancer. Most recently, Gemzar was approved in
Mexico for cervical cancer, making it the first approval for this disease.
Gemzar is a nucleoside analogue that interferes with the process of DNA
production; thereby preventing cancer cells from replicating and thus slows or
stops tumor growth.
Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Indiana, Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs. Additional
information about Lilly is available at http://www.lilly.com/ . P-LLY
This press release contains forward-looking statements about Gemzar in
combination with Taxotere and reflects Lilly's current beliefs. However, as
with any pharmaceutical product under development, there are substantial risks
and uncertainties in the process of development and commercialization. There
is no guarantee that the product will receive additional regulatory approvals
and there is also no guarantee that the product will continue to be
commercially successful. For further discussion of these and other risks and
uncertainties, see Lilly's filing with the United States Securities and
Exchange Commission. Lilly undertakes no duty to update forward-looking
statements.
(1) Evaluating the Impact of Neoadjuvant Chemotherapy and Surgery on Quality
of Life (QL) in Patients with Early Stage NSCLC: A Prospective Analysis as
part of the GINEST Project; RJ Gralla, MJ Edelman, FC Detterbeck, TM Jahan, D
Loesch, S Limentani, R Govindan, CK Obasaju, MA Socinski (Abstract # 8092)
(2) Neoadjuvant Chemotherapy with Gemcitabine-containing Regimens in Patients
with Early Stage Non-small Cell Lung Cancer (NSCLC): Initial Results of the
GINEST Project; F. Detterbeck, MA Socinski, RJ Gralla, MJ Edelman, TM Jahan, D
Loesch, S Limentani, R Govindan, LP Bloss, CK Obasaju (Abstract # 7215)
(3) Neoadjuvant chemotherapy with gemcitabine-containing regimens in stage
I-II Non-Small Cell Lung Cancer (NSCLC): Initial Results of pre- operative
pulmonary function testing (PFTs) in the GINEST Project; MP Rivera, FC
Detterbeck, MA Socinski, D Moore, MJ Edelman, TM Jahan, R Ansari, J Luketich,
CK Obasaju, RJ Gralla (Abstract # 7227)
(4) F. Detterbeck (Abstract # 7215)
(5) MP Rivera (Abstract # 7227)
(6) RJ Gralla (Abstract # 8092)
(7) Ibid.
(8) F. Detterbeck (Abstract # 7215)
(9) "Global cancer rates could increase by 50% to 15 million by 2020." World
Health Organization 3 April 2003; Accessed 26 April 2005
http://www.who.int/mediacentre/news/releases/2003/pr27/en/
Gemzar(R) (gemcitabine HCl, Lilly)
Taxol(R) (paclitaxel, Bristol-Myers Squibb)
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO
DATASOURCE: Eli Lilly and Company
CONTACT: Gregory L. Clarke (U.S. Media), +1-317-276-5222,
pager: +1-877-892-7864, or Carla L. Cox (non-U.S. Media), +1-317-651-1473,
pager: +1-888-446-5740, both of Eli Lilly and Company